NEW YORK, March 31, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Will Anyone Crack the Obesity Drug Market?
http://www.reportlinker.com/p0403345/Will-Anyone-Crack-the-Obesity-Drug-Market.html
Use this report to:
-Understand the state of play with Orexigen's Contrave
-Review the prevalence and impact of obesity
-Evaluate the therapeutic approaches being undertaken
-Critically assess and compare the approach and potential of products in clinical research with our unique product scoring
Around one in three of the global adult population and more than 20 million children under five are overweight according to the World Health Organization. Around 10% of adults are obese. In the US, an estimated 44.2% of males and 48.3% of females have a body mass index (BMI) of 30 or more and are classified as obese.
Orexigen's Contrave: possibly a new chapter – but when?
In December 2010, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted positively in favour of Orexigen's naltrexone sustained-release (SR) and bupropion SR combination, Contrave. The market was then surprised when the FDA did not approve the drug, asking instead for further clinical trials. If Contrave had been approved, it would have been the first new pharmacological treatment for obesity for more than a decade and would have immediately doubled the choice of available therapies; currently the only prescription drug that remains approved for obesity in the US and EU is Roche's Xenical (orlistat), a low-dose OTC version of which is marketed by GlaxoSmithKline as alli.
Report contents summary
-Executive summary
-Current market
-Future market
-Background information
-Product analysis by phase of development
This new report Will Anyone Crack the Obesity Drug Market, (published February 2011) provides a complete review of this difficult to develop area. Please note that web access is included at no additional cost.
Table of Contents
FOREWORD
EXECUTIVE SUMMARY
MARKET ANALYSIS
CURRENT MARKET
- Sibutramine
- Rimonabant
- Orlistat
FUTURE MARKET
- Research and Development
- Endogenous Hormones
- Monoamine Neurotransmission Modulation
- Neuropeptide Signalling Modulators
- Peripheral Modulators of Metabolism
- Regulation of Fat Metabolism and Food Intake: a Novel Approach?
BACKGROUND INFORMATION
- What is Obesity?
- What Causes Obesity
- Obesity Health Risks
- Controlling Energy Balance
- Achieving Weight Loss
- Lifestyle Modifications
- Behaviour Therapy
- Pharmacotherapy
- Surgery
- Why are New Treatments Needed?
- The Prevalence of Obesity
- Childhood Obesity
PRODUCT ANALYSIS
ESTABLISHED PRODUCT
- Orlistat
- Mode of Action
- Current Status
- Approvals/Filings
- Development
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Low-dose Orlistat
- Xenical in Adolescents
- Diabetes Prevention in Obese Subjects
RECENTLY WITHDRAWN PRODUCT
- Sibutramine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Clinical Trial Results
FILED PRODUCTS
- Bupropion+naltrexone
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Patent Expiry
- Competitor Ratio Analysis
- Clinical Trial Results
- Contrave Obesity Research (COR)
- Lorcaserin
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Patent Expiry
- Competitor Ratio Analysis
- Clinical Trial Results
- BLOSSOM
- BLOOM
- BLOOM-DM
- Abuse Potential
- Phentermine+topiramate
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Patent Expiry
- Competitor Ratio Analysis
- Clinical Trial Results
- Long-Term Date Show Significant and Sustained Weight Loss Over Two Years
- EQUIP (OB-302) and CONQUER (OB-303) Obesity Studies
- EQUATE Obesity Study
- Sleep Apnoea Phase II Study
PHASE III
- Cetilistat
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase IIb
- Liraglutide
- Mode of Action
- Current Status
- Approvals/Filings
- Development
- Proof of Concept/Clinical Data
- Diabetes
- Obesity
- Development Risks
- Company Expertise
- Competition within the Market-place
- Data Exclusivity
- Patent Expiry
- Competitor Ratio Analysis
- Clinical Trial Results
- Type II Diabetes
PHASE II
- Betahistine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Competitor Ratio Analysis
- Clinical Trial Results
- BET 209
- Obesity
- Pramlintide+metreleptin
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase II
- SLx-4090
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase II - Dyslipidaemia
- Phase I - Dyslipidaemia
- Phase I - Safety and Tolerability
- Tesofensine
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- TIPO-5
- TIPO-4
- TIPO-2
- TIPO-1
- Cardiovascular Safety Study
- TM30339
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Clinical Trial Results
- Phase I
- Velneperit
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase II
- Zonisamide+bupropion
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Competitor Ratio Analysis
- Clinical Trial Results
- Phase IIb
- Post hoc analyses
- Phase IIb results at 48 weeks
- Phase IIb results at 24 weeks
PHASE I/II
- BMS-830216
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Obinepitide
- Mode of Action
- Current Status
- Proof of Concept/Clinical Data
- Development Risks
- Company Expertise
- Competition within the Market-place
- Patents
- Clinical Trial Results
- Phase I/II
METHODOLOGY
- Competitor Ratio Analysis Criteria
List of Tables:
- Competitor Ratio Analysis Summary
- Drugs in Clinical Development for Obesity
- Relative Risks of Health Problems Associated with Obesity
- The Benefits of 10kg Weight Loss
List of Figures:
- Global Prevalence of Obesity, 2010
- Adult Male BMI kg/m2 in Selected Countries, 2010 (%)
- Adult Female BMI kg/m2 in Selected Countries, 2010 (%)
- Weight Loss Achieved With Orlistat
To order this report: Will Anyone Crack the Obesity Drug Market?
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker